Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Amortization of Deferred Charges: 2020-2025

Historic Amortization of Deferred Charges for Revolution Medicines (RVMD) over the last 2 years, with Sep 2025 value amounting to $11.4 million.

  • Revolution Medicines' Amortization of Deferred Charges was N/A to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year change of. This contributed to the annual value of $3.2 million for FY2021, which is 10.96% up from last year.
  • As of Q3 2025, Revolution Medicines' Amortization of Deferred Charges stood at $11.4 million, which was up 1,067.31% from $979,000 recorded in Q4 2021.
  • In the past 5 years, Revolution Medicines' Amortization of Deferred Charges ranged from a high of $11.4 million in Q3 2025 and a low of $691,000 during Q3 2021.
  • For the 1-year period, Revolution Medicines' Amortization of Deferred Charges averaged around $11.4 million, with its median value being $11.4 million (2025).
  • Over the last 5 years, Revolution Medicines' Amortization of Deferred Charges had its largest YoY gain of 28.99% in 2021, and its largest YoY loss of 1.00% in 2021.
  • Revolution Medicines' Amortization of Deferred Charges (Quarterly) stood at $979,000 in 2021, then followed by $11.4 million in 2025.
  • Its Amortization of Deferred Charges stands at $11.4 million for Q3 2025, versus $979,000 for Q4 2021 and $691,000 for Q3 2021.